Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Net Income (2016 - 2025)

ProQR Therapeutics' Net Income history spans 5 years, with the latest figure at -$10.6 million for Q4 2025.

  • On a quarterly basis, Net Income rose 1.7% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$49.0 million, a 48.58% decrease, with the full-year FY2025 number at -$49.1 million, down 65.51% from a year prior.
  • Net Income hit -$10.6 million in Q4 2025 for ProQR Therapeutics, up from -$13.2 million in the prior quarter.
  • Over the last five years, Net Income for PRQR hit a ceiling of -$3.9 million in Q2 2024 and a floor of -$20.0 million in Q3 2022.
  • Historically, Net Income has averaged -$12.6 million across 5 years, with a median of -$12.0 million in 2022.
  • Biggest five-year swings in Net Income: surged 59.75% in 2023 and later plummeted 257.65% in 2025.
  • Tracing PRQR's Net Income over 5 years: stood at -$19.8 million in 2021, then soared by 35.87% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then grew by 1.7% to -$10.6 million in 2025.
  • Business Quant data shows Net Income for PRQR at -$10.6 million in Q4 2025, -$13.2 million in Q3 2025, and -$13.9 million in Q2 2025.